GlassScriptPhysician profile
Raymond W Rozman
NPI 1265445530
$4,793.08
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,393 · 2020: $375 · 2021: $448 · 2022: $972 · 2023: $999 · 2024: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Education: $15.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.16 |
| Education | $15.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,479.61 | 2019-2024 | Rinvoq, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $875.12 | 2019-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $600.61 | 2019-2024 | Entyvio |
| Pfizer INC. | $334.19 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $264.24 | 2019-2024 | Dificid |
| Ardelyx, INC. | $202.07 | 2022-2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $189.14 | 2019-2020 | |
| Qol Medical, LLC | $175.97 | 2021-2024 | Sucraid, Sucraid |
| Celgene Corporation | $114.56 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $111.23 | 2020-2023 | |
| Janssen Biotech, INC. | $67.04 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $56.23 | 2022 | |
| Phathom Pharmaceuticals, INC. | $53.84 | 2024 | Voquezna |
| Vivus LLC | $41.46 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $33.08 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $28.80 | 2020 | |
| Genzyme Corporation | $27.44 | 2023 | |
| Allergan, INC. | $22.54 | 2019-2020 | |
| Organon LLC | $20.06 | 2024 | |
| Sandoz INC. | $19.21 | 2023 | Hyrimoz |
| Concordia Pharmaceuticals INC. | $18.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.60 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $14.79 | 2020 | |
| Braintree Laboratories, INC. | $14.40 | 2021 | |
| Shire North American Group INC | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Rozman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.